Long-term Safety and Efficacy Study of Ferriprox for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias
Phase of Trial: Phase IV
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Deferiprone (Primary)
- Indications Iron overload
- Focus Adverse reactions
- Acronyms FIRST
- Sponsors ApoPharma
- 10 Jun 2017 Biomarkers information updated
- 10 Mar 2017 Planned End Date changed from 1 Oct 2018 to 1 Dec 2021.
- 10 Mar 2017 Planned primary completion date changed from 1 May 2018 to 1 Jun 2021.